Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment

被引：0
|
作者：
Poplin, Elizabeth
Wasan, Harpreet
Rolfe, Lindsey
Raponi, Mitch
Ikdahl, Tone
Bondarenko, Ihor
Davidenko, Irina
Bondar, Volodymyr
Garin, August
Boeck, Stefan Hubert
Heinemann, Volker
Bassi, Claudio
Evans, T. R. Jeffry
Voong, Cynthia
Kaur, Paramjit
Isaacson, Jeffrey D.
Allen, Andrew R.
机构：
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA
[2] Imperial Coll Healthcare NHS Trust, London, England
[3] Clovis Oncol Inc, Boulder, CO USA
[4] Clovis Oncol Inc, San Francisco, CA USA
[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[6] Dnipropetrovsk State Med Acad, Dnepropetrovsk, Ukraine
[7] Krasnodar City Oncol Ctr, Krasnodar, Russia
[8] Donetsk Reg Antitumor Ctr, Donetsk, Ukraine
[9] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia
[10] Ludwig Maximilians Univ Munchen, Dept Hematol & Oncol, Klinikum Grosshadern, Munich, Germany
[11] Ludwig Maximilians Univ Munchen, Ctr Comprehens Canc, Munich, Germany
[12] Univ Munich, Klinikum Grosshadern, Dept Med Oncol, D-80539 Munich, Germany
[13] Univ Verona, Dept Surg, I-37100 Verona, Italy
[14] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4007
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F)
    Duffy, Austin G.
    Beg, Muhammad Shaalan
    Greten, Tim F.
    Beatson, Melony A.
    Mavroukakis, Sharon
    Patel, Sandip Pravin
    Morse, Michael A.
    Arlen, Philip M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [42] A randomized, multicenter, double-blind, placebo-controlled study of the Bruton tyrosine kinase inhibitor, ibrutinib, versus placebo in combination with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).
    Tempero, Margaret A.
    Coussens, Lisa M.
    Fong, Lawrence
    Manges, Robert
    Singh, Priyanka
    Li, Yunfeng
    Cole, George W.
    James, Danelle Frances
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12-and 18-month survival rates from the phase 3 NAPOLI 3 trial
    O'Reilly, Eileen Mary
    Melisi, Davide
    Macarulla, Teresa
    Roberto, A.
    Cid, Pazo
    Chandana, Sreenivasa R.
    De La Fouchardiere, Christelle
    Dean, Andrew Peter
    Kiss, Igor
    Lee, Woo Jin
    Goetze, Thorsten Oliver
    Van Cutsem, Eric
    Paulson, Scott
    Bekaii-Saab, Tanios S.
    Pant, Shubham
    Hubner, Richard
    Xiao, Zhimin
    Chen, Huanyu
    Benzaghou, Fawzi
    Wainberg, Zev A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
    Yamada, Daisaku
    Kobayashi, Shogo
    Takahashi, Hidenori
    Akita, Hirofumi
    Yamada, Terumasa
    Asaoka, Tadafumi
    Shimizu, Junzo
    Takeda, Yutaka
    Yokoyama, Shigekazu
    Tsujie, Masanori
    Tomokuni, Akira
    Tanemura, Masahiro
    Morimoto, Osakuni
    Murakami, Masahiro
    Kim, Yongkook
    Nakahira, Shin
    Hama, Naoki
    Sugimoto, Keishi
    Hashimoto, Kazuhiko
    Doki, Yuichiro
    Eguchi, Hidetoshi
    TRIALS, 2021, 22 (01)
  • [45] Phase 1 study of anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482+pembrolizumab plus gemcitabine plus nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Golan, Talia
    Cohen, Jonathan
    Voskoboynik, Mark
    Gutierrez, Martin
    Park, John J.
    Valente, Monica
    Renouf, Daniel John
    Liu, Qi
    Edmondson, Mackenzie
    Myer, Nicole
    Kapadia, Kishan J.
    Chen, Mei
    Victoria, Ivan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Renouf, D. J.
    Knox, J. J.
    Kavan, P.
    Jonker, D.
    Welch, S.
    Couture, F.
    Lemay, F.
    Tehfe, M.
    Harb, M.
    Aucoin, N.
    Ko, Y-J.
    Tang, P.
    Ramjeesingh, R.
    Meyers, B. M.
    Kim, C.
    Schaeffer, D. F.
    Loree, J.
    Gill, S.
    Tu, D.
    O'Callaghan, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1195 - S1195
  • [47] Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
    Daisaku Yamada
    Shogo Kobayashi
    Hidenori Takahashi
    Hirofumi Akita
    Terumasa Yamada
    Tadafumi Asaoka
    Junzo Shimizu
    Yutaka Takeda
    Shigekazu Yokoyama
    Masanori Tsujie
    Akira Tomokuni
    Masahiro Tanemura
    Osakuni Morimoto
    Masahiro Murakami
    Yongkook Kim
    Shin Nakahira
    Naoki Hama
    Keishi Sugimoto
    Kazuhiko Hashimoto
    Yuichiro Doki
    Hidetoshi Eguchi
    Trials, 22
  • [48] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
    Dean, Andrew
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Cutsem, Eric V.
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 202 - 203
  • [49] The Canadian Cancer Trials Group PA. 7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Renouf, Daniel John
    Dhani, Neesha C.
    Kavan, Petr
    Jonker, Derek J.
    Wei, Alice Chia-chi
    Hsu, Tina
    Tang, Patricia A.
    Graham, Barbara
    Gallinaro, Lisa
    Hasan, Tasnia
    Li, Weiwei
    Hart, Kate
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [50] ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
    Dean, A.
    Price, T. J.
    Sjoquist, K.
    Aryal, N.
    Mumford, J.
    Day, F.
    Yip, S.
    Walsh, A.
    Siu, D.
    Jackson, C.
    Padinharakam, S.
    Lee, B.
    Burge, M.
    Lynam, J.
    Tebbutt, N.
    Wong, Z. W. J.
    Lam, L. L.
    Lee, J.
    Chantrill, L.
    Harris, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1483 - S1483
12345